Evaluation of Losartan on Cardiovascular Disease in Patients With Mucopolysaccharidoses IV A and VI

study id #: NCT03632213

condition: Mucopolysaccharidosis IV A, Mucopolysaccharidosis VI, Mucopolysaccharidoses, MPS IV A, MPS VI, MPS - Mucopolysaccharidosis, Morquio A Syndrome, Morquio Syndrome A, Morquio Syndrome

status: Recruiting

Mucopolysaccharidoses (MPS) are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. For some of the cardiovascular manifestations, such as aortic root dilation and valve diseases, there is no effective treatment currently available. Losartan, on the other hand, has been shown to be an effective drug for dilation of the aortic root, at least in animal models. This study aims to evaluate the safety and efficacy of losartan in patients with MPS VI and other mucopolysaccharidoses.

intervention: Losartan, Placebo

results: https://clinicaltrials.gov/ct2/show/results/NCT03632213

last updated: February 26, 2022

start date: November 7, 2018

estimated completion: March 3, 2022

last updated: October 5, 2020

phase of development: Phase 2

size / enrollment: 30

study description: Mucopolysaccharidoses (MPS) are a group of lysosomal diseases characterized by deficiency of enzymes responsible for the degradation of glycosaminoglycans. MPS are multisystemic diseases with significant clinical overlap between their types, with cardiac problems being among the most commonly observed manifestations and are also among the main causes of mortality in these patients. Enzyme replacement therapy and bone marrow transplantation, despite being well established treatments, are not yet capable of reversing or preventing the progression of some of the cardiological manifestations of MPS. On the other hand, these patients may benefit from other conventional drug or surgical treatment, which can be instituted at an appropriate time if there is a better understanding of how these manifestations progress. In particular, the occurrence of aortic root dilation, although described in animal models, has only recently been evaluated in the studies on mucopolysaccharidoses.

In addition, verifying the effectiveness of losartan in controlling these manifestations in the animal model opens the perspective of clinical use of this drug. Losartan is a low-cost drug and, if its efficacy is demonstrated, may represent an accessible therapy directed at the unmet needs of these patients.

primary outcomes:

• Adverse events related to losartan use
  The frequency of adverse events after 12 months will be compared among the groups
• 12 months
  

secondary outcomes:

• Z score of maximal aortic root diameter measured by Valsalva sinus
  12 months
• Changes of serum levels of transforming growth factor (TGF-Beta-1)
  12 months
• Changes of serum levels of brain-type natriuretic peptide (BNP)
  12 months
• Changes of serum levels of N-terminal pro b-type natriuretic peptide (NT-ProBNP)
  12 months
• Changes of serum levels of creatine kinase-myocardial ban (ck-mb)
  12 months
• Changes of serum levels of Chemokine (C-X-C motif) ligand 6 (CXCL6)
  12 months
• Changes of serum levels of Chemokine (C-X-C motif) ligand 16 (CXCL16)
  12 months
• Changes of serum levels of Endocan-1 (ESM-1)
  12 months
• Changes of serum levels of Placental growth factor (PLGF)
  12 months
• Changes of serum levels of Fatty acid binding protein 3 (FAPB3)
  12 months
• Changes of serum levels of Fatty acid binding protein 4 (FAPB4)
  12 months
• Changes of serum levels of Oncostatin M
  12 months
• Changes of serum levels of Troponin I
  12 months
• Changes of ventricular-vascular coupling measures as assessed by echocardiography between the baseline and 12 months.
  12 months
• Changes in mitral valve regurgitation
  12 months
• Changes in aortic valve regurgitation
  12 months
• Changes in ejection fraction
  12 months
• Changes in left ventricular longitudinal strain
  12 months
• Changes in E/A ratio
  12 months
• Changes in E/e' ratio
  12 months

inclusion criteria:

exclusion criteria: Criteria:

Patient who underwent previous aortic surgery.
Patient with aortic root diameter greater than 5 cm.
Patient on angiotensin-converting-enzyme (ACE) inhibitor. In case of use of beta-blocker, or calcium channel blocker, patient without adequate control of blood pressure in the last 3 months.
Patients with previous adverse events related to treatment with losartan or contraindication to this treatment.
Inability, in the opinion of the investigator, to complete the study procedures.

sponsor: Hospital de Clinicas de Porto Alegre

contacts: Diane Pedrini, RN, +555133596340, dpedrini@hcpa.edu.br

investigators: Roberto Giugliani, MD, PhD,Hospital De Clinicas De Porto Alegre

trial center locations: Brazil

• Brazil, Rio Grande Do Sul
  Hospital de Clinicas de Porto Alegre
  Diane Pedrini, RN, +55 51 33596340, dpedrini@hcpa.edu.br